JP2016185988A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016185988A5 JP2016185988A5 JP2016145286A JP2016145286A JP2016185988A5 JP 2016185988 A5 JP2016185988 A5 JP 2016185988A5 JP 2016145286 A JP2016145286 A JP 2016145286A JP 2016145286 A JP2016145286 A JP 2016145286A JP 2016185988 A5 JP2016185988 A5 JP 2016185988A5
- Authority
- JP
- Japan
- Prior art keywords
- cell culture
- vaccine
- dna
- residual
- bpl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004113 cell culture Methods 0.000 claims 15
- 229960005486 vaccine Drugs 0.000 claims 13
- 238000000034 method Methods 0.000 claims 10
- 238000009472 formulation Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical group O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 4
- 229940100198 alkylating agent Drugs 0.000 claims 4
- 239000002168 alkylating agent Substances 0.000 claims 4
- 229960000380 propiolactone Drugs 0.000 claims 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 2
- 239000007764 o/w emulsion Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940031439 squalene Drugs 0.000 claims 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 2
- 210000002845 virion Anatomy 0.000 claims 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 238000001818 capillary gel electrophoresis Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 1
- 230000000593 degrading effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 210000003501 vero cell Anatomy 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73278605P | 2005-11-01 | 2005-11-01 | |
| US60/732,786 | 2005-11-01 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014149517A Division JP6639077B2 (ja) | 2005-11-01 | 2014-07-23 | β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016185988A JP2016185988A (ja) | 2016-10-27 |
| JP2016185988A5 true JP2016185988A5 (enExample) | 2017-01-05 |
| JP7049761B2 JP7049761B2 (ja) | 2022-04-07 |
Family
ID=37969762
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008538454A Active JP5602366B2 (ja) | 2005-11-01 | 2006-11-01 | β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
| JP2011206634A Withdrawn JP2011256209A (ja) | 2005-11-01 | 2011-09-21 | β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
| JP2014149517A Active JP6639077B2 (ja) | 2005-11-01 | 2014-07-23 | β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
| JP2016145286A Active JP7049761B2 (ja) | 2005-11-01 | 2016-07-25 | β－プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
| JP2019192740A Pending JP2020023557A (ja) | 2005-11-01 | 2019-10-23 | β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008538454A Active JP5602366B2 (ja) | 2005-11-01 | 2006-11-01 | β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
| JP2011206634A Withdrawn JP2011256209A (ja) | 2005-11-01 | 2011-09-21 | β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
| JP2014149517A Active JP6639077B2 (ja) | 2005-11-01 | 2014-07-23 | β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019192740A Pending JP2020023557A (ja) | 2005-11-01 | 2019-10-23 | β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10655108B2 (enExample) |
| EP (3) | EP2842572A1 (enExample) |
| JP (5) | JP5602366B2 (enExample) |
| KR (1) | KR20080081254A (enExample) |
| CN (2) | CN101365480B (enExample) |
| AT (1) | ATE494906T1 (enExample) |
| AU (2) | AU2006310171B2 (enExample) |
| CA (1) | CA2627971A1 (enExample) |
| CY (1) | CY1111378T1 (enExample) |
| DE (1) | DE602006019629D1 (enExample) |
| DK (1) | DK1951296T4 (enExample) |
| EA (1) | EA014062B1 (enExample) |
| ES (2) | ES2525518T3 (enExample) |
| HK (1) | HK1207828A1 (enExample) |
| NZ (1) | NZ567817A (enExample) |
| PL (2) | PL2301572T3 (enExample) |
| PT (1) | PT2301572E (enExample) |
| SI (1) | SI1951296T2 (enExample) |
| WO (1) | WO2007052163A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2842572A1 (en) * | 2005-11-01 | 2015-03-04 | Novartis Vaccines and Diagnostics GmbH | Cell-derived viral vaccines with low levels of residual cell dna |
| PL1976559T6 (pl) | 2006-01-27 | 2020-08-10 | Novartis Influenza Vaccines Marburg Gmbh | Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy |
| EP2066345B1 (en) | 2006-09-11 | 2015-02-25 | Novartis AG | Making influenza virus vaccines without using eggs |
| EA201070066A1 (ru) | 2007-06-27 | 2010-06-30 | Новартис Аг | Вакцины против гриппа с низким содержанием добавок |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| US20110014230A1 (en) | 2008-03-18 | 2011-01-20 | Novartis Ag | preparation of influenza virus vaccine antigens |
| CA2741961A1 (en) | 2008-11-05 | 2010-05-14 | Glaxosmithkline Biologicals S.A. | Novel method |
| JP2012525370A (ja) | 2009-04-27 | 2012-10-22 | ノバルティス アーゲー | インフルエンザに対して防御するためのアジュバント添加ワクチン |
| EP2401384B1 (en) | 2009-05-21 | 2012-10-03 | Novartis AG | Reverse genetics using non-endogenous pol i promoters |
| JP2013500712A (ja) | 2009-07-31 | 2013-01-10 | ノバルティス アーゲー | 逆遺伝学系 |
| CN102648003B (zh) | 2009-10-09 | 2016-01-13 | 儿童医疗中心有限公司 | 选择性裂解的全细胞疫苗 |
| NZ599479A (en) | 2009-10-20 | 2013-11-29 | Novartis Ag | Improved reverse genetics methods for virus rescue |
| BR112012027643A2 (pt) | 2010-05-03 | 2016-08-16 | Glaxosmithkline Biolog Sa | métodos para a inativação de um orthomixovírus, para a preparação de uma vacina, e , composição imunogênica |
| KR20130079398A (ko) | 2010-05-06 | 2013-07-10 | 노파르티스 아게 | 미생물 불활성화를 위한 유기 과산화 화합물 |
| CA2800150C (en) | 2010-05-21 | 2018-09-04 | Novartis Ag | Influenza virus reassortment method |
| ES2825712T3 (es) | 2010-06-01 | 2021-05-17 | Seqirus Uk Ltd | Concentración de antígenos de vacuna contra la influenza sin liofilización |
| CN102939104A (zh) | 2010-06-01 | 2013-02-20 | 诺华有限公司 | 用冻干浓缩疫苗抗原 |
| CN103052399B (zh) | 2010-08-12 | 2016-06-29 | 依生生物制药控股有限公司 | 用于减少病毒组合物中dna杂质的方法 |
| ES2531577T3 (es) | 2010-08-20 | 2015-03-17 | Novartis Ag | Conjuntos de agujas para la administración de vacuna soluble contra la gripe |
| KR20140006963A (ko) | 2011-02-25 | 2014-01-16 | 노파르티스 아게 | 외래 내부 양성 대조군 |
| EP3290050B1 (en) | 2011-11-03 | 2019-01-02 | Sentinext Therapeutics SDN BHD | Vaccines directed against human enteroviruses |
| GB2495341B (en) | 2011-11-11 | 2013-09-18 | Novartis Ag | Fermentation methods and their products |
| CA2813723A1 (en) | 2012-03-02 | 2013-09-02 | Novartis Ag | Influenza virus reassortment |
| JP5918870B2 (ja) | 2012-03-06 | 2016-05-18 | クルセル ホランド ベー ヴェー | インフルエンザに対する改善されたワクチン接種 |
| AU2013270793A1 (en) | 2012-06-04 | 2014-12-11 | Novartis Ag | Improved safety testing |
| EP2925356A2 (en) | 2012-12-03 | 2015-10-07 | Novartis AG | Reassortant influenza a viren |
| JP6525469B2 (ja) | 2013-03-13 | 2019-06-05 | ノバルティス アーゲー | インフルエンザｂ型ウイルス再集合 |
| CA2911296A1 (en) | 2013-05-10 | 2014-11-13 | Wayne Volkmuth | Avoiding narcolepsy risk in influenza vaccines |
| DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
| DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
| US10329537B2 (en) | 2013-06-06 | 2019-06-25 | Seqirus UK Limited | Influenza virus reassortment |
| CN104436157A (zh) | 2013-09-23 | 2015-03-25 | 恩金生物有限公司 | 流感疫苗和治疗 |
| US10080792B2 (en) | 2013-09-23 | 2018-09-25 | Engen Bio, Inc. | Influenza vaccine and therapy |
| CN104513317B (zh) * | 2013-09-30 | 2018-12-14 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法和应用 |
| WO2015071177A1 (en) | 2013-11-15 | 2015-05-21 | Novartis Ag | Removal of residual cell culture impurities |
| CN106661102B (zh) * | 2014-05-28 | 2021-01-26 | 财团法人卫生研究院 | 作为对抗肠病毒感染之免疫原的病毒颗粒及其制造 |
| WO2016207853A2 (en) | 2015-06-26 | 2016-12-29 | Seqirus UK Limited | Antigenically matched influenza vaccines |
| KR102790570B1 (ko) | 2015-07-07 | 2025-04-04 | 세퀴러스 유케이 리미티드 | 인플루엔자 효능 검정 |
| EP3184119A1 (en) * | 2015-12-23 | 2017-06-28 | Themis Bioscience GmbH | Chromatography based purification strategies for measles scaffold based viruses |
| ES2991988T3 (es) | 2017-10-30 | 2024-12-05 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica |
| CN109652384B (zh) * | 2019-02-21 | 2021-10-26 | 昆明理工大学 | 一种体外培养戊型肝炎病毒的方法 |
| EP4054630A2 (en) * | 2019-11-07 | 2022-09-14 | Seqirus UK Limited | Compositions and methods for producing a viral vaccine with reduced particle size |
| AU2020389047A1 (en) | 2019-11-18 | 2022-06-02 | Seqirus Pty Ltd. | Method for producing reassortant influenza viruses |
| AU2022251654A1 (en) * | 2021-03-30 | 2023-10-12 | Denka Company Limited | Influenza vaccine |
| CN115354071A (zh) * | 2022-08-10 | 2022-11-18 | 上海药明生基医药科技有限公司 | 一种检测重组腺相关病毒宿主细胞dna残留的方法 |
| CN116407624B (zh) * | 2023-04-14 | 2024-04-09 | 吉林省农业科学院(中国农业科技东北创新中心) | 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用 |
| TW202516000A (zh) * | 2023-07-25 | 2025-04-16 | 日商Ｋｍ生物醫藥股份有限公司 | 利用雞蛋培養法進行的去活化流感疫苗的製備方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH589453A5 (enExample) * | 1974-01-14 | 1977-07-15 | Sandoz Ag | |
| US4064232A (en) * | 1974-01-14 | 1977-12-20 | Sandoz Ltd. | Process for isolating the immunogenic components of influenza viruses |
| US4140762A (en) * | 1974-01-14 | 1979-02-20 | Sandoz Ltd. | Influenza sub-unit vaccine |
| EP0251575B2 (en) | 1986-06-17 | 2002-11-13 | Chiron Corporation | Hepatitis delta diagnostics and vaccines, their preparation and use |
| GB8703696D0 (en) * | 1987-02-18 | 1987-03-25 | Oxford J S | Influenza vaccine |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5010183A (en) | 1989-07-07 | 1991-04-23 | Macfarlane Donald E | Process for purifying DNA and RNA using cationic detergents |
| JP2941859B2 (ja) | 1989-09-20 | 1999-08-30 | 国立予防衛生研究所 | Ｈａ蛋白の製造法 |
| US5010112A (en) * | 1989-12-01 | 1991-04-23 | Massachusetts Institute Of Technology | Method and apparatus for improving the insulating properties of closed cell foam |
| US5824536A (en) | 1994-08-23 | 1998-10-20 | St. Jude Children's Research Hospital | Influenza virus replicated in mammalian cell culture and vaccine production |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| TW570803B (en) * | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| JP4610735B2 (ja) * | 1998-06-01 | 2011-01-12 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | ワクチン抗原およびアジュバントの粘膜送達のためのヒアルロン酸ポリマーの使用 |
| JP2000230931A (ja) | 1998-12-07 | 2000-08-22 | Katakura Industries Co Ltd | 家畜インフルエンザウイルスに対する抗体の検出方法およびこれに用いるキット |
| EP1187629B1 (en) * | 1999-04-19 | 2004-09-22 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| DE60036952T2 (de) | 1999-09-24 | 2008-08-07 | Glaxosmithkline Biologicals S.A. | Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung |
| EP1103610A1 (en) | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
| WO2001041814A1 (en) | 1999-12-08 | 2001-06-14 | Crucell Holland B.V. | Method of administering adenovirus |
| JP4698112B2 (ja) | 2000-03-03 | 2011-06-08 | 一般財団法人化学及血清療法研究所 | 無血清培養かつ浮遊培養可能な細胞及び当該細胞を用いたワクチン用ウイルスの製造法 |
| FR2808803B1 (fr) | 2000-05-11 | 2004-12-10 | Agronomique Inst Nat Rech | Cellules es modifiees et gene specifique de cellules es |
| GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
| JP5208347B2 (ja) * | 2001-02-23 | 2013-06-12 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規なワクチン |
| WO2002067983A1 (en) | 2001-02-23 | 2002-09-06 | Glaxosmithkline Biologicals S.A. | Novel vaccine |
| WO2002087494A2 (en) | 2001-04-27 | 2002-11-07 | Glaxosmithkline Biologicals, Sa | Novel vaccine |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
| DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
| DE10144903A1 (de) | 2001-09-12 | 2003-03-27 | Chiron Behring Gmbh & Co | Vermehrung von Viren in Zellkultur |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| EP2497826A1 (en) | 2002-04-26 | 2012-09-12 | MedImmune, LLC | Method of producing a temperature sensitive (ts) influenza virus |
| EP1590450A2 (en) | 2002-12-20 | 2005-11-02 | Crucell Holland B.V. | Recombinant virus production for the manufacturing of vaccines |
| CA2522379C (en) | 2003-04-10 | 2012-10-23 | Chiron Corporation | The severe acute respiratory syndrome coronavirus |
| NZ543446A (en) | 2003-05-28 | 2008-06-30 | Wisconsin Alumni Res Found | High titer recombinant influenza viruses for vaccines and gene therapy |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| EP1780269B1 (en) | 2004-02-23 | 2009-07-08 | Crucell Holland B.V. | Virus purification methods |
| WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
| NZ551640A (en) | 2004-05-20 | 2010-05-28 | Id Biomedical Corp | Process for the production of an influenza vaccine |
| SI2236155T1 (sl) * | 2004-09-09 | 2012-09-28 | Novartis Vaccines & Diagnostic | Zmanjšanje potencialnih iatrogenih tveganj, povezanih s cepivi proti influenci |
| JP4031478B2 (ja) | 2004-12-13 | 2008-01-09 | プロテイン サイエンシーズ | インフルエンザ血球凝集素多価ワクチンの製造方法 |
| DK2368975T3 (en) | 2004-12-23 | 2015-01-05 | Medimmune Llc | Non-tumorigenic MDCK cell line for the propagation of viruses |
| FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
| EP2842572A1 (en) * | 2005-11-01 | 2015-03-04 | Novartis Vaccines and Diagnostics GmbH | Cell-derived viral vaccines with low levels of residual cell dna |
| SG174813A1 (en) * | 2006-09-15 | 2011-10-28 | Medimmune Llc | Mdck cell lines supporting viral growth to high titers and bioreactor process using the same |
-
2006
- 2006-11-01 EP EP14183359.0A patent/EP2842572A1/en not_active Ceased
- 2006-11-01 CN CN200680046034.8A patent/CN101365480B/zh not_active Expired - Fee Related
- 2006-11-01 PT PT100755297T patent/PT2301572E/pt unknown
- 2006-11-01 DK DK06831855.9T patent/DK1951296T4/da active
- 2006-11-01 CN CN201410631136.2A patent/CN104474543A/zh active Pending
- 2006-11-01 DE DE602006019629T patent/DE602006019629D1/de active Active
- 2006-11-01 EP EP10075529.7A patent/EP2301572B1/en not_active Revoked
- 2006-11-01 ES ES10075529.7T patent/ES2525518T3/es active Active
- 2006-11-01 CA CA002627971A patent/CA2627971A1/en not_active Abandoned
- 2006-11-01 NZ NZ567817A patent/NZ567817A/en not_active IP Right Cessation
- 2006-11-01 JP JP2008538454A patent/JP5602366B2/ja active Active
- 2006-11-01 SI SI200630957T patent/SI1951296T2/sl unknown
- 2006-11-01 EP EP06831855.9A patent/EP1951296B2/en active Active
- 2006-11-01 PL PL10075529T patent/PL2301572T3/pl unknown
- 2006-11-01 KR KR1020087013164A patent/KR20080081254A/ko not_active Ceased
- 2006-11-01 WO PCT/IB2006/003880 patent/WO2007052163A2/en not_active Ceased
- 2006-11-01 AU AU2006310171A patent/AU2006310171B2/en active Active
- 2006-11-01 EA EA200801221A patent/EA014062B1/ru not_active IP Right Cessation
- 2006-11-01 US US12/092,190 patent/US10655108B2/en active Active
- 2006-11-01 AT AT06831855T patent/ATE494906T1/de active
- 2006-11-01 ES ES06831855.9T patent/ES2359214T5/es active Active
- 2006-11-01 PL PL06831855T patent/PL1951296T5/pl unknown
-
2011
- 2011-04-05 CY CY20111100356T patent/CY1111378T1/el unknown
- 2011-04-29 AU AU2011201968A patent/AU2011201968B2/en active Active
- 2011-09-21 JP JP2011206634A patent/JP2011256209A/ja not_active Withdrawn
-
2014
- 2014-07-23 JP JP2014149517A patent/JP6639077B2/ja active Active
-
2015
- 2015-09-01 HK HK15108523.2A patent/HK1207828A1/en unknown
-
2016
- 2016-07-25 JP JP2016145286A patent/JP7049761B2/ja active Active
-
2019
- 2019-10-23 JP JP2019192740A patent/JP2020023557A/ja active Pending
-
2020
- 2020-04-09 US US16/843,940 patent/US11466257B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016185988A5 (enExample) | ||
| US12365880B2 (en) | Recombinant influenza viruses with stabilized NA | |
| Wong et al. | Traditional and new influenza vaccines | |
| Rockman et al. | New technologies for influenza vaccines | |
| Bergmann-Leitner et al. | Adjuvants in the driver’s seat: how magnitude, type, fine specificity and longevity of immune responses are driven by distinct classes of immune potentiators | |
| JP2013537518A5 (enExample) | ||
| JP2014532620A5 (enExample) | ||
| JP6300827B2 (ja) | ケイ化ウイルスを含む免疫原性組成物および使用の方法 | |
| CO2018005229A2 (es) | Vacuna de virus sincitial respiratorio | |
| JP2016155867A5 (enExample) | ||
| Atmar et al. | Adjuvants for pandemic influenza vaccines | |
| JP2011504486A5 (enExample) | ||
| Yan et al. | Protection of chickens against infectious bronchitis virus with a multivalent DNA vaccine and boosting with an inactivated vaccine | |
| Fawzy et al. | Nanoparticles as a novel and promising antiviral platform in veterinary medicine | |
| B. Carvalho et al. | Downstream processing for influenza vaccines and candidates: An update | |
| Wang et al. | The potential adjuvanticity of quaternized chitosan hydrogel based microparticles for porcine reproductive and respiratory syndrome virus inactivated vaccine | |
| JP2019520090A (ja) | 弱毒変異型ジカウイルスを含むワクチン組成物 | |
| JP2025072575A (ja) | インフルエンザウイルスバックボーン | |
| US11123421B2 (en) | Cold adapted and virulence factor deleted live attenuated vaccine suitable for mucosal delivery | |
| CA2722558A1 (en) | Methods for preparing immunogenic compositions | |
| RU2599496C2 (ru) | Улучшенная вакцинация против гриппа | |
| Abdoli et al. | An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice | |
| Mokalla et al. | Influenza vaccines: current status, adjuvant strategies, and efficacy | |
| Lei et al. | Intranasal immunization of recombinant Lactococcus lactis induces protection against H5N1 virus in ferrets | |
| Hernandez et al. | Particle and subunit-based hemagglutinin vaccines provide protective efficacy against H1N1 influenza in pigs |